Grifols GRFS
NASDAQ GRFS
$8.00 +0.01 (+0.13%)
At close: Aug 21, 2026 · 4:00 PM EDT

Grifols (GRFS) Non Operating Interest Expenses (2010 - 2014)

Grifols' (GRFS) quarterly Non Operating Interest Expenses came in at $74.9 million in Q4 2014, up 14.34% YoY from $65.5 million in Q4 2013, and up 14.34% on a QoQ basis from $65.5 million in Q4 2013.

Grifols (GRFS) Non Operating Interest Expenses (2010 - 2014) Analysis & Trends

Grifols (GRFS) has 5 years of Non Operating Interest Expenses data on file, last reported at $74.9 million in Q4 2014.

  • Quarterly Non Operating Interest Expenses rose 14.34% year-over-year to $74.9 million in Q4 2014, while the trailing twelve-month figure through Dec 2014 was $626.3 million (up 42.47% YoY) and the FY2014 annual result came in at $79.6 million, up 24.63% from the prior year.
  • Non Operating Interest Expenses improved to $74.9 million in Q4 2014, from $65.5 million in the prior quarter.
  • In the past five years, Non Operating Interest Expenses ranged from a high of $429.6 million in Q4 2011 to a low of -$111.8 million in Q3 2011.
  • A 5-year average of $90.5 million and a median of $65.5 million in 2013 frame the typical range for Non Operating Interest Expenses.
  • The widest YoY moves for Non Operating Interest Expenses: up 248.68% in 2011, down 2628.45% in 2011.
  • Tracing GRFS's Non Operating Interest Expenses over 5 years: stood at $123.2 million in 2010, then soared by 248.68% to $429.6 million in 2011, then sank by 86.89% to $56.3 million in 2012, then increased by 16.27% to $65.5 million in 2013, then gained by 14.34% to $74.9 million in 2014.
  • The last three Non Operating Interest Expenses figures came in at $74.9 million (Q4 2014), $65.5 million (Q4 2013), and $56.3 million (Q4 2012), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Johnson & Johnson 652.20 Bn 631.44 Bn 17.26 Bn 281.00 Mn
2 AbbVie 469.51 Bn 462.94 Bn 12.70 Bn -
3 Merck 376.81 Bn 369.67 Bn 12.21 Bn -
4 Novartis Ag 303.04 Bn 295.35 Bn 11.24 Bn 462.00 Mn
5 Astrazeneca 257.61 Bn 252.71 Bn 12.86 Bn 435.00 Mn
6 Amgen 237.37 Bn 223.38 Bn 7.24 Bn 673.00 Mn
7 Gilead Sciences 181.73 Bn 178.55 Bn 6.22 Bn 247.00 Mn
8 Pfizer 159.66 Bn 147.96 Bn 10.94 Bn -
9 Gsk 106.24 Bn 102.07 Bn 8.24 Bn -244.19 Mn
10 Grifols 5.45 Bn 4.45 Bn - -

Historic Data

Download Data
DateValue
Dec 31, 2014 74.88 Mn
Dec 31, 2013 65.49 Mn
Dec 31, 2012 56.32 Mn
Dec 31, 2011 429.63 Mn
Sep 30, 2011 -111.83 Mn
Dec 31, 2010 123.21 Mn
Sep 30, 2010 -4.10 Mn